Perspective Therapeutics, Inc. (CATX)
Market Cap | 707.34M |
Revenue (ttm) | -304,000 |
Net Income (ttm) | -58.42M |
Shares Out | 67.43M |
EPS (ttm) | -1.90 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 863,272 |
Open | 11.14 |
Previous Close | 11.20 |
Day's Range | 10.47 - 11.36 |
52-Week Range | 2.10 - 19.10 |
Beta | 1.43 |
Analysts | Strong Buy |
Price Target | 22.00 (+109.72%) |
Earnings Date | Aug 9, 2024 |
About CATX
Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as L... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for CATX stock is "Strong Buy." The 12-month stock price forecast is $22.0, which is an increase of 109.72% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/w/c/press10-2475131.jpg)
Perspective Therapeutics Announces Inclusion in the Russell 3000® Index
SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment ap...
![](https://cdn.snapi.dev/images/v1/r/p/press16-2472878.jpg)
Perspective Therapeutics Announces 1-for-10 Reverse Stock Split
SEATTLE, June 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment ap...
![](https://cdn.snapi.dev/images/v1/i/v/press3-2472152.jpg)
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
SEATTLE, June 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment ap...
![](https://cdn.snapi.dev/images/v1/n/k/press20-2447058.jpg)
Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
SEATTLE, May 24, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment app...
![](https://cdn.snapi.dev/images/v1/z/1/conf16-2439251.jpg)
Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024
SEATTLE, May 20, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment app...
![](https://cdn.snapi.dev/images/v1/i/p/press4-2431658.jpg)
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results
SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment app...
![](https://cdn.snapi.dev/images/v1/o/n/conf3-2408709.jpg)
Perspective Therapeutics to Participate at Upcoming May Investor Conferences
SEATTLE, May 03, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment ap...
![](https://cdn.snapi.dev/images/v1/l/d/press4-2405508.jpg)
Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results
SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout ...
![](https://cdn.snapi.dev/images/v1/n/o/press3-2399275.jpg)
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers through...
![](https://cdn.snapi.dev/images/v1/f/s/conf1-2360734.jpg)
Perspective Therapeutics to Participate at Upcoming April Investor Conferences
SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment ...
![](https://cdn.snapi.dev/images/v1/c/d/press11-2345893.jpg)
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers througho...
![](https://cdn.snapi.dev/images/v1/h/y/press9-2306476.jpg)
Perspective Therapeutics Announces $87.4 Million Private Placement
SEATTLE, March 04, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment a...
![](https://cdn.snapi.dev/images/v1/j/x/press13-2255195.jpg)
Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform
SEATTLE, Feb. 01, 2024 (GLOBE NEWSWIRE) -- -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatme...
![](https://cdn.snapi.dev/images/v1/u/c/press18-2239103.jpg)
Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement
SEATTLE, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment ap...
![](https://cdn.snapi.dev/images/v1/w/a/press17-2234000.jpg)
Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement
SEATTLE, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment a...
![](https://cdn.snapi.dev/images/v1/q/r/press12-2233371.jpg)
Perspective Therapeutics Announces Proposed Public Offering
SEATTLE, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment ap...
![](https://cdn.snapi.dev/images/v1/k/e/press4-2232300.jpg)
Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01
SEATTLE, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced that it began patient recruitment for the second dosing cohorts (Cohort 2) in clinical ...
![](https://cdn.snapi.dev/images/v1/7/z/press1-2222045.jpg)
Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability
SEATTLE, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced it entered into strategic agreements with Lantheus Holdings, Inc., the leading radiop...
![](https://cdn.snapi.dev/images/v1/c/4/conf20-2213060.jpg)
Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that Thijs Spoor, the Company's Chief Executive Office...
![](https://cdn.snapi.dev/images/v1/n/v/press20-2187261.jpg)
Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine Tumors
SEATTLE, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announced today that the first patient was dosed at the University of...
![](https://cdn.snapi.dev/images/v1/3/z/press1-2158090.jpg)
Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights
SEATTLE, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced third quarter financial results for the period ended September 30, 2023 and provided re...
![](https://cdn.snapi.dev/images/v1/g/u/press7-2104337.jpg)
Perspective Therapeutics Completes Recruitment for First Patient Cohort in Phase 1/2a Dose Escalation Trial of VMT01 in Malignant Melanoma
SEATTLE, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced the completion of recruitment for the first patient co...
![](https://cdn.snapi.dev/images/v1/a/m/press10-2092211.jpg)
Perspective Therapeutics' Cesium-131 Featured at the American Society for Radiation Oncology's Annual Conference
SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and c...
![](https://cdn.snapi.dev/images/v1/t/b/conf20-2042874.jpg)
Perspective Therapeutics to Present at the World Molecular Imaging Congress 2023
RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Perspective T h erapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will have two pr...
![](https://cdn.snapi.dev/images/v1/j/j/press7-2019304.jpg)
Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma
RICHLAND, Wash. & CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, In c. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announces the first patient was dosed at...